10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-RAD17 Antibody [KO/KD Validated]

Catalog # AP60378

Product Information

Application	WB, IHC, IF/IC
Primary Accession	O75943
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	77055

Additional Information

Gene ID	5884
Other Names	R24L; Cell cycle checkpoint protein RAD17; hRad17; RF-C/activator 1 homolog
Target/Specificity	KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human RAD17. The exact sequence is proprietary.
Dilution	WB~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500) IHC~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500) IF/IC~~N/A
Format	Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Storage	Store at -20 °C.Stable for 12 months from date of receipt

Protein Information

Name	RAD17 {ECO:0000303|PubMed:9878245, ECO:0000312|HGNC:HGNC:9807}
Function	Essential for sustained cell growth, maintenance of chromosomal stability, and ATR-dependent checkpoint activation upon DNA damage (PubMed:10208430, PubMed:11418864, PubMed:11687627, PubMed:11799063, PubMed:12672690, PubMed:14624239, PubMed:15235112). Has a weak ATPase activity required for binding to chromatin (PubMed:10208430, PubMed:11418864, PubMed:11687627, PubMed:11799063, PubMed:12672690, PubMed:14624239, PubMed:15235112). Participates in the recruitment of the 9-1-1 (RAD1-RAD9-HUS1) complex and RHNO1 onto chromatin, and in CHEK1 activation (PubMed:21659603). Involved in homologous recombination by mediating recruitment of the MRN complex to DNA damage sites (PubMed:24534091). May also serve as a sensor of DNA replication progression (PubMed:12578958, PubMed:14500819, PubMed:15538388).
Cellular Location	Nucleus. Chromosome Note=Phosphorylated form redistributes to discrete

nuclear foci upon DNA damage (PubMed:11799063). Localizes to DNA double-strand breaks (DSBs) (PubMed:24534091).

Tissue Location

Overexpressed in various cancer cell lines and in colon carcinoma (at protein level). Isoform 2 and isoform 3 are the most abundant isoforms in non irradiated cells (at protein level) Ubiquitous at low levels. Highly expressed in testis, where it is expressed within the germinal epithelium of the seminiferous tubuli Weakly expressed in seminomas (testicular tumors)

Images



Western blot analysis of RAD17 expression in Hela (A) whole cell lysates. (Predicted band size: 77 kD; Observed band size: 80 kD)



Immunohistochemical analysis of RAD17 staining in human lung cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.



Immunofluorescent analysis of RAD17 staining in A549 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.

Immunohistochemical analysis of RAD17 staining in human lung cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with



haematoxylin and mounted with DPX.



Western blot analysis of RAD17 expression in wild type (WT) and knockdown (KD) HeLa cell lysates.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.